Share on StockTwits

Pacira Pharmaceuticals (NASDAQ:PCRX)‘s stock had its “buy” rating restated by stock analysts at Jefferies Group in a report issued on Tuesday, American Banking News.com reports. They currently have a $81.00 price target on the stock. Jefferies Group’s price target points to a potential upside of 20.88% from the stock’s previous close.

Pacira Pharmaceuticals (NASDAQ:PCRX) traded up 2.20% during mid-day trading on Tuesday, hitting $67.01. The stock had a trading volume of 505,470 shares. Pacira Pharmaceuticals has a 52 week low of $24.70 and a 52 week high of $83.41. The stock has a 50-day moving average of $68.4 and a 200-day moving average of $61.73. The company’s market cap is $2.259 billion.

Pacira Pharmaceuticals (NASDAQ:PCRX) last released its earnings data on Tuesday, February 25th. The company reported ($0.33) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.31) by $0.02. On average, analysts predict that Pacira Pharmaceuticals will post $-0.56 earnings per share for the current fiscal year.

A number of other firms have also recently commented on PCRX. Analysts at Bank of America initiated coverage on shares of Pacira Pharmaceuticals in a research note on Monday, April 21st. They set a “buy” rating on the stock. Separately, analysts at Piper Jaffray upgraded shares of Pacira Pharmaceuticals from a “neutral” rating to an “overweight” rating in a research note on Tuesday, April 1st. They now have a $84.00 price target on the stock, up previously from $75.00. Finally, analysts at National Alliance Securities initiated coverage on shares of Pacira Pharmaceuticals in a research note on Tuesday, March 18th. They set a “buy” rating and a $109.41 price target on the stock. One investment analyst has rated the stock with a sell rating and seven have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $75.40.

Pacira Pharmaceuticals, Inc is a United States-based pharmaceutical company. The Company develops non-opioid products for postsurgical pain control.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.